| 1.03 0.03 (3%) | 05-23 10:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.27 |
1-year : | 1.46 |
| Resists | First : | 1.08 |
Second : | 1.25 |
| Pivot price | 1.03  |
|||
| Supports | First : | 0.82 |
Second : | 0.69 |
| MAs | MA(5) : | 0.99 |
MA(20) : | 1.04 |
| MA(100) : | 1.04 |
MA(250) : | 1.08 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 23.5 |
D(3) : | 19.3 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 3.23 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ESLA ] has closed above bottom band by 45.4%. Bollinger Bands are 15.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.01 - 1.02 | 1.02 - 1.02 |
| Low: | 0.99 - 0.99 | 0.99 - 1 |
| Close: | 0.99 - 1 | 1 - 1.01 |
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Mon, 05 May 2025
Geode Capital Management LLC Acquires 16,862 Shares of Estrella Immunopharma, Inc. (NASDAQ:ESLA) - Defense World
Wed, 12 Mar 2025
Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews
Wed, 05 Mar 2025
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - Yahoo Finance
Fri, 21 Feb 2025
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - Business Wire
Fri, 27 Sep 2024
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Wed, 14 Aug 2024
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 36 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 72 (%) |
| Held by Institutions | 0.8 (%) |
| Shares Short | 2 (K) |
| Shares Short P.Month | 23 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -4.25 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|